Progression-Free Survival and Quality of Life in Oncology Clinical Trials

A methods project investigating the relationship between progression-free survival (PFS) and patient psychological well-being or quality of life (QOL). The work involved systematic literature searches in MEDLINE, PubMed, Embase, and CENTRAL for studies from 2005 to 2010 on drugs approved based on PFS outcomes. No direct evidence was found linking knowledge of PFS to psychological well-being, but four studies were identified examining the association between PFS and QOL or disease symptoms.

Use Cases

• Analyzing the relationship between progression-free survival and quality-of-life measures based on the described literature review.
• Investigating the use of PFS as a surrogate endpoint for patient well-being based on the project's key questions.
• Reviewing evidence on specific oncology drugs (e.g., Avastin, Sutent) approved based on PFS outcomes and their impact on disease symptoms.

Strengths

• Systematic review methodology involving a Technical Expert Panel and searches across four major databases (MEDLINE, PubMed, Embase, CENTRAL).
• Focus on a defined set of oncology drugs approved by regulatory agencies between 2005 and 2010.
• Includes a quality assessment of individual studies to identify potential biases in measuring PFS or QOL.

Limitations

• Row count and column-level documentation are unknown, which limits suitability assessment.
• The dataset appears to be a summary of a literature review; the underlying raw data is not available.
• Last update date is unknown; freshness unverified.

Provenance

Source

paperswithcode

Collection Method

Literature review and data abstraction from relevant clinical studies.

Time Range

Studies from 2005 to 2010 were included in the search.